Blue Earth Diagnostics wins prestigious ‘Best Emerging Biotech’ award

12 October 2018

Oxford, UK – October 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, has won the Oxford Bio Network (OBN) award for “Best Emerging Biotech ”. These prestigious OBN awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry. The OBN’s “Best Emerging Biotech ” award goes to a company which has:

• Evidence of a credible product pipeline

• Proof of significant clinical trial activity

• Made an impact on the industry via significant news flow

• Proof of continued fundraising • Evidence of a strong team in place

• Proof of developing partnerships and collaborations

• Clear evidence of a robust business plan to support continued growth

• Been incorporated in the UK after 2013 but before 1 June 2016

Dr. Jonathan Allis, the founding CEO of Blue Earth Diagnostics commented, “Our mission is to help improve the lives of patients with cancer by developing innovative imaging technologies to inform and guide treatment decisions. Winning this award is a great honour and great recognition of the commitment, talent and hard work of the whole Blue Earth Diagnostics team towards our goal. I would like to extend my sincere congratulations to the team and to all the other finalists.” About Blue Earth Diagnostics

Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men with a diagnosis of biochemical recurrence. The company’s pipeline includes Prostate Specific Membrane Antigen (PSMA)targeted radiohybrid (“rh”) agents. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer. Blue Earth Diagnostics is backed by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit: www.blueearthdiagnostics.com.

About OBN

The OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities. For more information please visit: www.obn.org.uk.

Contacts: Blue Earth Diagnostics (Europe)

Georgina Mowatt

Communications Manager

Tel: +44 (0) 7810 355 912

g.mowatt@blueearthdx.com

Read other news articles